Pharma BD Deal Intelligence
GSK acquired Aiolos Bio for $1.0B upfront plus up to $400M in success-based regulatory milestones (announced 2024-01-09, completed 2024-02-15) to add a Phase 2-ready, long-acting anti-TSLP monoclonal antibody, AIO-001 (now GSK5784283; also SHR-1905), to its respiratory franchise. AIO-001's potency and half-life extension support potential dosing as infrequently as every six months for adult asthma, positioning GSK against Amgen/AstraZeneca's Tezspire. The asset entered a Phase 2 dose-finding asthma study (NCT06748053) in February 2025.